SAP sued by o9 Solutions over alleged trade secret theft
Investing.com - Guggenheim lowered its price target on Inventiva SA (NASDAQ:IVA) to $11.00 from $13.00 on Tuesday while maintaining a Buy rating on the stock. Currently trading at $4.06, IVA shares remain well below the analyst consensus target, with price targets ranging from $3 to $26 according to InvestingPro data.
The price target adjustment follows Inventiva’s announcement of $172.5 million (or €149.0 million) in equity financing, which the company plans to use to fund the continuation of its NATiV3 Phase 3 trial. This financing comes as InvestingPro data shows the company is quickly burning through cash, with an EBITDA of -$112.83 million over the last twelve months.
The biopharmaceutical company will also use the funds for preparation and initiation of its outcome trial, as well as for commercialization activities.
Guggenheim’s revised price target represents a $4.4 billion valuation on a fully diluted basis, with the firm reiterating its Buy rating ahead of the NATiV3 Phase 3 results expected in the second half of 2026.
The research firm believes Inventiva’s treatment has potential to be a "best in-class oral antifibrotic MASH treatment" that could compete with resmetirom from Madrigal Pharmaceuticals.
In other recent news, Inventiva has successfully raised approximately $150 million through a public offering of American Depositary Shares (ADS) in the United States. The offering, which priced each ADS at $3.85, is expected to close on November 17, 2025, and is aimed at funding the company’s MASH treatment initiatives. Trading of Inventiva’s ordinary shares on Euronext Paris resumed following a temporary halt to facilitate the ADS allocation process. Piper Sandler has reiterated an Overweight rating on Inventiva, maintaining a positive outlook with a $26.00 price target, based on the prospects of the company’s lead drug candidate, lanifibranor. H.C. Wainwright has also raised its price target for Inventiva to $24.00 from $20.00, maintaining a Buy rating. Stifel continues to support the company with a Buy rating and a $17.00 price target, emphasizing lanifibranor’s unique mechanism of action. These developments highlight the ongoing interest and confidence in Inventiva’s therapeutic advancements in the MASH space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.